Professor Claude M. Wischik, co-founder and Executive Chairman of TauRx Therapeutics, along with colleagues at the University of Aberdeen, has devoted nearly 30 years to investigating the structure and role of tau tangles in the development of Alzheimer’s, frontotemporal dementia and other neurodegenerative diseases. Prof. Wischik discovered that the neurofibrillary tangles seen in Alzheimer’s disease are made of sub-units of the tau protein and he and his team have published extensively in the field.

Deiana, S, et al. (2009) Methylthioninium chloride reverses cognitive deficits induced by scopolamine: comparison with rivastigmine. Available at Psychopharmacology.

Luna-Muñoz, J, et al. (2009) In pre-tangle cells truncation at Asp-421 along the C-terminus of tau protein appears to precede that of the Glu-391 in Alzheimer´s disease. Available at Alzheimer's & Dementia.

Melis, V, et al. (2009) Age-related impairments in Tau transgenic mice using two different water maze training protocols. Available at Alzheimer's & Dementia

Mukaetova-Ladinska, E. B., et al. (2009) Lewy body variant of Alzheimer's disease: selective neocortical loss of t-SNARE proteins and loss of MAP2 and alpha-synuclein in medial temporal lobe. Available at: The Scientific World Journal.

Wischik, C.M., Staff, R., (2009) Challenges in the conduct of disease-modifying trials in Alzheimer's disease: practical experience from a phase 2 trial of TAU-aggregation inhibitor therapy. Available at Journal Nutrition, Health & Aging